top of page

ATX

Amplia Therapeutics Ltd

Biotechnology

·

Healthcare

5

comments

4

fund managers

past 90 days

About Amplia Therapeutics Ltd

Amplia Therapeutics Ltd. is an Australian biotechnology company based in Melbourne. Founded in 2000, the firm specializes in developing drug candidates for oncology and chronic fibrosis. Its core platform utilizes immuno-modulator microparticles designed to activate the immune system against cancers and infections, while also modulating mechanisms related to autoimmune conditions like multiple sclerosis. The company remains focused on drug development across these therapeutic areas.

Commentary Volume

5

Comments

4

Fund managers

0

Past 90 days

SOURCE

ACTION

COMMENT PREVIEW

FUND MANAGER

DATE

Loading...

Source: Ipsum Capital Q4 Quarterly Letter  ·  Published 14 March 2025

Loading...

.

​Loading...

Loading...

Loading...

Loading...

Loading...

Source: Ipsum Capital Q4 Quarterly Letter  ·  Published 14 March 2025

Report a problem

Loading...

.

Loading...

Loading...

Loading...

Loading...

14 Mar 2025

ic

Ipsum Capital

"Lorem ipsum dolor sit amet...

Q4 Letter

14 Mar 2025

ic

Dolor Investments

"Lorem ipsum dolor sit amet...

Q4 Letter

🔒 21 more comments from 10 sources

Unlock full access

§ Important Notice

The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.

Commentary

Sector

Healthcare

Market cap

$67M

Fund managers

4 managers

First covered

31 Oct 2024

Last updated

31 Mar 2026

Company Details

Related Themes

ic

Ipsum Capital

6 comments

ic

Amet Funds

4 comments

ic

Dolor

3 comments

Top Investors Covering MIN

§ Reminder

The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.

Frequently asked questions about Amplia Therapeutics Ltd (ASX:ATX)

Frequently asked questions

Who is investing in Amplia Therapeutics Ltd (ASX:ATX)?

Fund managers including Pengana Capital Group, SG Hiscock & Company, Acorn Capital and Pengana Capital have invested in Amplia Therapeutics Ltd (ASX:ATX).

What is the short interest in Amplia Therapeutics Ltd (ASX:ATX)?

The short interest in Amplia Therapeutics Ltd (ASX:ATX) is 0.05% which makes it the 452nd most shorted stock on the ASX. Of the 513.1M shares that Amplia Therapeutics Ltd has on issue, 276.7K have been sold short.

What does Amplia Therapeutics Ltd (ASX:ATX) do?

Amplia Therapeutics Ltd. is an Australian biotechnology company based in Melbourne. Founded in 2000, the firm specializes in developing drug candidates for oncology and chronic fibrosis. Its core platform utilizes immuno-modulator microparticles designed to activate the immune system against cancers and infections, while also modulating mechanisms related to autoimmune conditions like multiple sclerosis. The company remains focused on drug development across these therapeutic areas.

bottom of page